Onur Yazdan Balçık
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Onur Yazdan Balçık has a total of 112 co-authors. Here are the top co-authors by number of shared publications:
- Hacer Demir
Department of Medical Oncology, Afyonkarahisar Health Sciences University, Afyonkarahisar 03030, Turkey
4 shared publications - Murat Araz
Department of Medical Oncology, Necmettin Erbakan University School of Medicine, Konya, Turkey
4 shared publications - Muslih Ürün
Department of Medical Oncology, Faculty of Medicine, Van Yuzuncu Yil University, Van 65090, Türkiye
4 shared publications Yusuf İlHan
Department of Medical Oncology, Antalya City Hospital, Antalya, Turkey
4 shared publications- Berrak Mermit Ercek
Department of Medical Oncology, Van Yüzüncü Yıl University, Van 65080, Turkey
3 shared publications - Canan Yıldız
Department of Medical Oncology, Afyonkarahisar Health Sciences University, Afyonkarahisar 03030, Türkiye
3 shared publications
Latest Publications
- 1 March 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 12 (3) , e2500655
Resectable Stage Early-Onset Biliary Tract Cancer: Survival and Prognostic Scoring (EOB-RS and EOB-OS) in Turkish Patients (TOG/GI-SAFRADJU-2502-EO)
PURPOSE: Early-onset gastrointestinal cancers are concerning entities globally, yet early-onset biliary tract cancers (EOBTCs) are understudied. Early-stage disease is crucial for young patients' survival. METHODS: TOG/GI-SAFRADJU (ClinicalTrials.gov identifier: NCT06975917 ) is a multicenter, hospital-based, registry initiative of the Turkish Oncology Group, including patients with resected BTCs. Early-onset was defined as a diagnosis at age v 25.7%, P = .038). Adjuvant treatments did not differ between EOBTC and non-EOBTC. Among patients who received adjuvant chemotherapy, RFS (13.9 months [95% CI, 11.4 to 22.1] v 15.9 months [95% CI, 13.6 to 18.9], P = .947) and OS (35.6 months [95% CI, 28.0 to 81.4] v 31.3 months [95% CI, 27.8 to 44.3], P = .670) were similar between EOBTC and non-EOBTC groups. Among patients with EOBTC, R1-resection and high CA19-9 levels were associated with shorter RFS, and gallbladder localization and high CA19-9 were associated with shorter OS in adjusted analyses. Using these factors, risk scores early-stage EOBTC RFS score (EOB-RS) for RFS and early-stage EOBTC OS score (EOB-OS) for OS were formed, each including three ranks. Both scores significantly ordered the prognosis of patients with EOBTC (EOB-RS, [0 points]: 22.7 months, [1 or 2]: 10.3 months, [3]: 5.7 months, P < .001, EOB-OS: [0]: 110.9 months, [1 or 2]: 29.6 months, [3]: 10.1 months, P < .001). CONCLUSION: Resected EOBTC patients showed survival comparable to older counterparts receiving surgery/adjuvant therapy. This study suggests a potential risk scoring system for early-stage EOBTC, pending validation.
- 1 March 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 12 (3) , e2500655
Resectable Stage Early-Onset Biliary Tract Cancer: Survival and Prognostic Scoring (EOB-RS and EOB-OS) in Turkish Patients (TOG/GI-SAFRADJU-2502-EO)
PURPOSE: Early-onset gastrointestinal cancers are concerning entities globally, yet early-onset biliary tract cancers (EOBTCs) are understudied. Early-stage disease is crucial for young patients' survival. METHODS: TOG/GI-SAFRADJU (ClinicalTrials.gov identifier: NCT06975917 ) is a multicenter, hospital-based, registry initiative of the Turkish Oncology Group, including patients with resected BTCs. Early-onset was defined as a diagnosis at age v 25.7%, P = .038). Adjuvant treatments did not differ between EOBTC and non-EOBTC. Among patients who received adjuvant chemotherapy, RFS (13.9 months [95% CI, 11.4 to 22.1] v 15.9 months [95% CI, 13.6 to 18.9], P = .947) and OS (35.6 months [95% CI, 28.0 to 81.4] v 31.3 months [95% CI, 27.8 to 44.3], P = .670) were similar between EOBTC and non-EOBTC groups. Among patients with EOBTC, R1-resection and high CA19-9 levels were associated with shorter RFS, and gallbladder localization and high CA19-9 were associated with shorter OS in adjusted analyses. Using these factors, risk scores early-stage EOBTC RFS score (EOB-RS) for RFS and early-stage EOBTC OS score (EOB-OS) for OS were formed, each including three ranks. Both scores significantly ordered the prognosis of patients with EOBTC (EOB-RS, [0 points]: 22.7 months, [1 or 2]: 10.3 months, [3]: 5.7 months, P < .001, EOB-OS: [0]: 110.9 months, [1 or 2]: 29.6 months, [3]: 10.1 months, P < .001). CONCLUSION: Resected EOBTC patients showed survival comparable to older counterparts receiving surgery/adjuvant therapy. This study suggests a potential risk scoring system for early-stage EOBTC, pending validation.
- 13 February 2026
- Published by Taylor & Francis in Biomarkers
- Vol. 31 (2) , 91-100
Evaluation of inflammatory parameters and ferritin as prognostic factors in non-small cell lung cancer patients receiving nivolumab immunotherapy
AimInflammation and immune dysfunction significantly impact cancer progression and treatment responses. This retrospective study investigated inflammatory parameters and ferritin in predicting immunotherapy response in non-small cell lung cancer (NSCLC) patients.MethodsThe study included 199 patients with NSCLC who received nivolumab between 2018 and 2024 at five medical centers. Various inflammatory markers were also evaluated. Ferritin levels at diagnosis and pretreatment were also evaluated.ResultsROC curve analyses showed ferritin delta had high prognostic performance for PFS and OS, with AUC values of 0.70 and 0.73. PIV and PNI were significantly associated with PFS and OS. In Kaplan-Meier analyses, PNI was the most consistent prognostic factor. Low PNI (≤43.5) significantly associated with shorter OS (5.0 vs. 15.0 months, p = 0.001) and shorter PFS (4.0 vs. 8.0 months, p = 0.002). High mGPS (score 2) and elevated PIV showed significant prognostic value. In multivariate Cox regression, PNI demonstrated independent prognostic significance. Objective response rate was the strongest prognostic factor for PFS (HR = 0.188, 95%CI: 0.114-0.309, p < 0.001).ConclusionThese findings highlight the prognostic value of inflammatory and nutritional markers in patients with NSCLC receiving immunotherapy. PNI demonstrated the most consistent prognostic value across multiple analytical approaches and maintained significance in the multivariate analysis.
- 13 February 2026
- Published by Taylor & Francis in Biomarkers
- Vol. 31 (2) , 91-100
Evaluation of inflammatory parameters and ferritin as prognostic factors in non-small cell lung cancer patients receiving nivolumab immunotherapy
AimInflammation and immune dysfunction significantly impact cancer progression and treatment responses. This retrospective study investigated inflammatory parameters and ferritin in predicting immunotherapy response in non-small cell lung cancer (NSCLC) patients.MethodsThe study included 199 patients with NSCLC who received nivolumab between 2018 and 2024 at five medical centers. Various inflammatory markers were also evaluated. Ferritin levels at diagnosis and pretreatment were also evaluated.ResultsROC curve analyses showed ferritin delta had high prognostic performance for PFS and OS, with AUC values of 0.70 and 0.73. PIV and PNI were significantly associated with PFS and OS. In Kaplan-Meier analyses, PNI was the most consistent prognostic factor. Low PNI (≤43.5) significantly associated with shorter OS (5.0 vs. 15.0 months, p = 0.001) and shorter PFS (4.0 vs. 8.0 months, p = 0.002). High mGPS (score 2) and elevated PIV showed significant prognostic value. In multivariate Cox regression, PNI demonstrated independent prognostic significance. Objective response rate was the strongest prognostic factor for PFS (HR = 0.188, 95%CI: 0.114-0.309, p < 0.001).ConclusionThese findings highlight the prognostic value of inflammatory and nutritional markers in patients with NSCLC receiving immunotherapy. PNI demonstrated the most consistent prognostic value across multiple analytical approaches and maintained significance in the multivariate analysis.
- 1 January 2026
- Published by Kare Publishing in Eurasian Journal of Medical Investigation
- Vol. 10 (4) , 559-570
Prognostic Significance of the Prognostic Nutritional Index and HALP Score in Patients with Metastatic Gastrointestinal Stromal Tumors: A Multicenter Retrospective Study
Ejmi Eurasian Journal of Medical Investigation
- 1 January 2026
- Published by Kare Publishing in Eurasian Journal of Medical Investigation
- Vol. 10 (4) , 559-570
Prognostic Significance of the Prognostic Nutritional Index and HALP Score in Patients with Metastatic Gastrointestinal Stromal Tumors: A Multicenter Retrospective Study
Ejmi Eurasian Journal of Medical Investigation
- 23 November 2025
- Published by Wiley in The Prostate
- Vol. 86 (3) , 393-400
Prognostic Effect of KELIM Score of Prostate‐Specific Antigen in Hormone‐Sensitive Prostate Cancer Patients Treated With Novel Androgen Receptor Inhibitors: Pioneering New Ways
Background: The prognostic value of the PSA ELIMination rate constant K (PRO‐KELIM) score was investigated in patients with metastatic castration‐sensitive prostate cancer (mCSPC) treated with novel androgen receptor inhibitors. Methods: This multicenter retrospective study included 160 patients diagnosed with prostate adenocarcinoma between 2011 and 2024 who received enzalutamide or abiraterone during the mCSPC and had at least three PSA measurements within the first 100 days of treatment. The patients were categorized into favorable (PRO‐KELIM ≥ 1.0) and unfavorable (PRO‐KELIM < 1.0) groups. Progression‐free survival (PFS) and overall survival (OS) were analyzed using the Kaplan–Meier survival analysis and Cox regression. Results: Median PFS was significantly higher in the favorable group than in the unfavorable group (not reached vs. 40.0 months, p < 0.001). The estimated 2‐year PFS rates in the favorable and unfavorable groups were 78% and 52%, respectively. In multivariate analyses, a high PRO‐KELIM score (HR 2.99; 95% CI 1.35–6.66, p = 0.007) and good initial response to treatment ( p = 0.001) were independent favorable prognostic factors for PFS. The median OS did not differ significantly between the groups ( p = 0.27). PRO‐KELIM score was not an independent prognostic factor for OS ( p = 0.76). Conclusion: These findings suggest that the PRO‐KELIM score can be a valuable prognostic tool in the mCSPC to assess early treatment response and predict disease progression.
- 23 November 2025
- Published by Wiley in The Prostate
- Vol. 86 (3) , 393-400
Prognostic Effect of KELIM Score of Prostate‐Specific Antigen in Hormone‐Sensitive Prostate Cancer Patients Treated With Novel Androgen Receptor Inhibitors: Pioneering New Ways
Background: The prognostic value of the PSA ELIMination rate constant K (PRO‐KELIM) score was investigated in patients with metastatic castration‐sensitive prostate cancer (mCSPC) treated with novel androgen receptor inhibitors. Methods: This multicenter retrospective study included 160 patients diagnosed with prostate adenocarcinoma between 2011 and 2024 who received enzalutamide or abiraterone during the mCSPC and had at least three PSA measurements within the first 100 days of treatment. The patients were categorized into favorable (PRO‐KELIM ≥ 1.0) and unfavorable (PRO‐KELIM < 1.0) groups. Progression‐free survival (PFS) and overall survival (OS) were analyzed using the Kaplan–Meier survival analysis and Cox regression. Results: Median PFS was significantly higher in the favorable group than in the unfavorable group (not reached vs. 40.0 months, p < 0.001). The estimated 2‐year PFS rates in the favorable and unfavorable groups were 78% and 52%, respectively. In multivariate analyses, a high PRO‐KELIM score (HR 2.99; 95% CI 1.35–6.66, p = 0.007) and good initial response to treatment ( p = 0.001) were independent favorable prognostic factors for PFS. The median OS did not differ significantly between the groups ( p = 0.27). PRO‐KELIM score was not an independent prognostic factor for OS ( p = 0.76). Conclusion: These findings suggest that the PRO‐KELIM score can be a valuable prognostic tool in the mCSPC to assess early treatment response and predict disease progression.
- Open Access
- 30 August 2025
- Published by SAGE Publications in Therapeutic Advances in Medical Oncology
- Vol. 17
Comparison of the efficacy of mFOLFOX-6 and mDCF regimens in the treatment of metastatic gastric cancer: a multicenter retrospective study
Background: Metastatic gastric cancer (GC) and gastroesophageal junction (GEJ) cancer are associated with a poor prognosis. Recent advancements in treatment have incorporated trastuzumab, anti-PD-1 agents, and anti-claudin therapies alongside chemotherapy (ChT), significantly improving outcomes. Contemporary studies predominantly employ doublet ChT as the backbone for these regimens, although historically triplet ChT regimens have been favored, particularly in younger patients requiring rapid tumor shrinkage. Objective: The aim of this study was to compare the efficacy of mFOLFOX-6 and mDCF regimens in the treatment of advanced GC and GEJ adenocarcinoma. Design: This was a retrospective multicenter study. Methods: Patient data were obtained from the databases of 25 hospitals across Turkey. Demographic and clinicopathological characteristics were documented. Overall survival (OS) and progression-free survival (PFS) were analyzed using the Kaplan–Meier method, and group discrepancies were assessed with log-rank test. Results: A total of 493 patients were included in the analysis, with similar baseline characteristics between the two groups. The objective response rate was 36.3% in the mDCF group and 38% in the mFOLFOX-6 group ( p = 0.7). The median PFS was 6 months for mDCF and 7 months for mFOLFOX-6 ( p = 0.2), while the median OS was 12 months for mDCF and 11 months for mFOLFOX-6 ( p = 0.4). Grade 3–4 neutropenia occurred in 27.6% of patients treated with mDCF versus 17.8% with mFOLFOX-6 ( p = 0.01). Likewise, grade 3–4 anemia was more frequent in the mDCF group (9.5%) compared to the mFOLFOX-6 group (4.8%; p = 0.04). Conclusion: Modified FOLFOX-6 demonstrated comparable efficacy to mDCF in the treatment of advanced GC and GEJ adenocarcinoma. Moreover, mFOLFOX-6 was associated with a lower incidence of hematological adverse effects.
- 30 August 2025
- Published by SAGE Publications in Therapeutic Advances in Medical Oncology
- Vol. 17
Open AccessComparison of the efficacy of mFOLFOX-6 and mDCF regimens in the treatment of metastatic gastric cancer: a multicenter retrospective study
Background: Metastatic gastric cancer (GC) and gastroesophageal junction (GEJ) cancer are associated with a poor prognosis. Recent advancements in treatment have incorporated trastuzumab, anti-PD-1 agents, and anti-claudin therapies alongside chemotherapy (ChT), significantly improving outcomes. Contemporary studies predominantly employ doublet ChT as the backbone for these regimens, although historically triplet ChT regimens have been favored, particularly in younger patients requiring rapid tumor shrinkage. Objective: The aim of this study was to compare the efficacy of mFOLFOX-6 and mDCF regimens in the treatment of advanced GC and GEJ adenocarcinoma. Design: This was a retrospective multicenter study. Methods: Patient data were obtained from the databases of 25 hospitals across Turkey. Demographic and clinicopathological characteristics were documented. Overall survival (OS) and progression-free survival (PFS) were analyzed using the Kaplan–Meier method, and group discrepancies were assessed with log-rank test. Results: A total of 493 patients were included in the analysis, with similar baseline characteristics between the two groups. The objective response rate was 36.3% in the mDCF group and 38% in the mFOLFOX-6 group ( p = 0.7). The median PFS was 6 months for mDCF and 7 months for mFOLFOX-6 ( p = 0.2), while the median OS was 12 months for mDCF and 11 months for mFOLFOX-6 ( p = 0.4). Grade 3–4 neutropenia occurred in 27.6% of patients treated with mDCF versus 17.8% with mFOLFOX-6 ( p = 0.01). Likewise, grade 3–4 anemia was more frequent in the mDCF group (9.5%) compared to the mFOLFOX-6 group (4.8%; p = 0.04). Conclusion: Modified FOLFOX-6 demonstrated comparable efficacy to mDCF in the treatment of advanced GC and GEJ adenocarcinoma. Moreover, mFOLFOX-6 was associated with a lower incidence of hematological adverse effects.
- 19 February 2025
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 81 (4) , 561-570
Prognostic value of IMDC score in non-small cell lung cancer receiving immunotherapy: old dog, new tricks?
Background Although there are multiple treatment options, oncologists lack appropriate biomarkers for determining the efficacy and toxicity of immunotherapy. In this study, we aimed to use a combination of the clinical parameters of IMDC risk groups at the time of diagnosis to predict the effectiveness of immunotherapy. Methods This multicenter cross-sectional study retrospectively analyzed non-small cell lung cancer (NSCLC) patients receiving nivolumab for the prognostic effects of clinical factors, including the IMDC score. Results Two hundred and five patients were enrolled in this study. There was no favorable group because the TTI was less than 1 year in the entire study group in the IMDC. The IMDC score and IMDC groups showed significant differences in PFS (p < 0.001; p < 0.001, respectively). Intermediate and poor-risk groups had PFS of 8 and 3 months PFS, respectively. The IMDC group showed a significant effect on OS (p = 0.002). The intermediate- and poor-risk groups had 12- and 4-month OS, respectively. The TTI risk factor excluded patient numbers in the favorable, intermediate, and poor risk groups were 47, 129, and 29, respectively, in the revised IMDC group (rIMDC). The prognostic effect of the rIMDC score and groups remained significant (p < 0.001 and p < 0.001, respectively). The classical IMDC had a significant effect on PFS in the multivariate analysis (p = 0.016). Also, rIMDC score in multivariate analysis resulted with significant effect on OS (p = 0.035). Conclusion To date, this is the first study to prove that the IMDC may be a valuable option for predicting both prognosis and treatment efficacy in NSCLC patients receiving especially second or further lines nivolumab treatment.
- 19 February 2025
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 81 (4) , 561-570
Prognostic value of IMDC score in non-small cell lung cancer receiving immunotherapy: old dog, new tricks?
Background Although there are multiple treatment options, oncologists lack appropriate biomarkers for determining the efficacy and toxicity of immunotherapy. In this study, we aimed to use a combination of the clinical parameters of IMDC risk groups at the time of diagnosis to predict the effectiveness of immunotherapy. Methods This multicenter cross-sectional study retrospectively analyzed non-small cell lung cancer (NSCLC) patients receiving nivolumab for the prognostic effects of clinical factors, including the IMDC score. Results Two hundred and five patients were enrolled in this study. There was no favorable group because the TTI was less than 1 year in the entire study group in the IMDC. The IMDC score and IMDC groups showed significant differences in PFS (p < 0.001; p < 0.001, respectively). Intermediate and poor-risk groups had PFS of 8 and 3 months PFS, respectively. The IMDC group showed a significant effect on OS (p = 0.002). The intermediate- and poor-risk groups had 12- and 4-month OS, respectively. The TTI risk factor excluded patient numbers in the favorable, intermediate, and poor risk groups were 47, 129, and 29, respectively, in the revised IMDC group (rIMDC). The prognostic effect of the rIMDC score and groups remained significant (p < 0.001 and p < 0.001, respectively). The classical IMDC had a significant effect on PFS in the multivariate analysis (p = 0.016). Also, rIMDC score in multivariate analysis resulted with significant effect on OS (p = 0.035). Conclusion To date, this is the first study to prove that the IMDC may be a valuable option for predicting both prognosis and treatment efficacy in NSCLC patients receiving especially second or further lines nivolumab treatment.
- Open Access
- 1 January 2025
- Published by XMLink in Journal of Gastric Cancer
- Vol. 25 (4) , 523-525
Rethinking Neoadjuvant Therapy: A Critical Evaluation of Exclusion Criteria in Gastric Cancer Surgery Studies
Ilhan Y, et al. J Gastric Cancer. 2025 Mar;25:e19. https://doi.org/10.5230/jgc.2025.25.e19
- 1 January 2025
- Published by XMLink in Journal of Gastric Cancer
- Vol. 25 (4) , 523-525
Open AccessRethinking Neoadjuvant Therapy: A Critical Evaluation of Exclusion Criteria in Gastric Cancer Surgery Studies
Ilhan Y, et al. J Gastric Cancer. 2025 Mar;25:e19. https://doi.org/10.5230/jgc.2025.25.e19
- 12 December 2024
- Published by Elsevier in Urologic Oncology: Seminars and Original Investigations
- Vol. 43 (4) , 268.e9-268.e26
FOXP3/TLS; a prognostic marker in patients with bladder carcinoma without muscle invasion
- 12 December 2024
- Published by Elsevier in Urologic Oncology: Seminars and Original Investigations
- Vol. 43 (4) , 268.e9-268.e26
FOXP3/TLS; a prognostic marker in patients with bladder carcinoma without muscle invasion
- Open Access
Positive Lymph Node Ratio as a new prognostic score in Geriatric patients with operated gastric cancer
- Open Access
- 29 October 2023
- Published by Acta Medica Alanya in Acta Medica Alanya
- Vol. 7 (2) , 153-162
Prognostic significance of PNI, SIRI and LIPI in non small-cell lung cancer
Aim: Non-small cell lung cancer (NSCLC) is one of the 3 most common and deadly cancers. The aim of the current study is to investigate whether Prognostic Nutritional Index /PNI), Systemic Immune-Inflammation Index (SIRI), Lung Immune Prognostic Index (LIPI) has a prognostic significance in patients with metastatic NSLCL. Methods: Patients diagnosed with pathologically confirmed metastatic NSCLC in 5 different hospitals in Turkey between 2016-2022 were included in our study and analyzed retrospectively. overall survival (OS) and progression-free survival (PFS) were recorded. Results: The median PFS was 5.50 months, while the median OS was 16.03 months. Median OS was 14.86 months for the PNI-Low group and 17.2 months for the PNI-High group (p: <0.121). The median OS of the PNI-Low group was shorter than the PNI-High group, but there was no statistically significant difference between the groups. Median OS was 19.86 months for the SIRI-Low group and 14.23 months for the SIRI-High group (p: <0.112). Median OS was 17.76, 15.13, 13.73 months for the LIPI-Low, LIPI-intermediate group and LIPI-high group, there was no statistically significant difference between the groups (p: <0.391) Conclusion: In conclusion, PNI and SIRI may be significant in a prospective study in a specific patient group to be performed with a larger number of patients to predict the prognosis of patients with metastatic NSCLC.
- 29 October 2023
- Published by Acta Medica Alanya in Acta Medica Alanya
- Vol. 7 (2) , 153-162
Open AccessPrognostic significance of PNI, SIRI and LIPI in non small-cell lung cancer
Aim: Non-small cell lung cancer (NSCLC) is one of the 3 most common and deadly cancers. The aim of the current study is to investigate whether Prognostic Nutritional Index /PNI), Systemic Immune-Inflammation Index (SIRI), Lung Immune Prognostic Index (LIPI) has a prognostic significance in patients with metastatic NSLCL. Methods: Patients diagnosed with pathologically confirmed metastatic NSCLC in 5 different hospitals in Turkey between 2016-2022 were included in our study and analyzed retrospectively. overall survival (OS) and progression-free survival (PFS) were recorded. Results: The median PFS was 5.50 months, while the median OS was 16.03 months. Median OS was 14.86 months for the PNI-Low group and 17.2 months for the PNI-High group (p: <0.121). The median OS of the PNI-Low group was shorter than the PNI-High group, but there was no statistically significant difference between the groups. Median OS was 19.86 months for the SIRI-Low group and 14.23 months for the SIRI-High group (p: <0.112). Median OS was 17.76, 15.13, 13.73 months for the LIPI-Low, LIPI-intermediate group and LIPI-high group, there was no statistically significant difference between the groups (p: <0.391) Conclusion: In conclusion, PNI and SIRI may be significant in a prospective study in a specific patient group to be performed with a larger number of patients to predict the prognosis of patients with metastatic NSCLC.